02-19-02

PTO/SB/05 (03-01)

Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE on Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ا ح	Ω }P th
Z.	4
F	U.S
\$	•
	ΡTC

UTILITY PATENT APPLICATION TRANSMITTAL

Attorr	ney Docket No.	REG 780D	ဉ
First Inventor		Andrew J. Murphy	, d
Title	Methods of Mod	difying Eukaryotic Cells	S.D.

(Only for new nonprovision	al applications under 37 CFR 1.53(b))	Express	IVIAII Label IVO. ET7	12521705	005		
APPLICATION ELEMENTS			ADDRESS TO: Assistant Commissioner for Pate ts Box Patent Application				
See MPEP chapter 600 conc	erning utility patent application content	s	Wasi	nington, E	OC 202	231	
Applicant claims sr See 37 CFR 1.27. 3. X Specification (preferred arrangement - Descriptive title - Cross Reference - Statement Rega - Reference to se or a computer p - Background of t - Brief Summary - Brief Description - Detailed Description - Claim(s) - Abstract of the	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i CD-ROM or CD-R (2 copies); or i i. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS						
- Brief Description	n of the Drawings (<i>if filed</i>)						
X Drawing(s) (35 U.S.C. 113) [Total Sheets 7] 11. English Translation Document (if applicable)					Power of Attorney		
5. Oath or Declaration	[Total Pages] 12	Information Disclose Statement (IDS)/PT		L	☐ Citations	
a. Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) 13. Preliminary Amendment Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						,	
	ION OF INVENTOR(S)	15.	Certified Copy of P (if foreign priority is	claimed)	Junien	11(5)	
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1 63(d)(2) and 1.33(b) 6. Application Data Sheet. See 37 CFR 1 76						U.S.C. 122 form PTO/SB/35	
18. If a CONTINUING APPLI	CATION, check appropriate box, and	supply the requ	isite information below a	and in a p	relimir	nary amendment,	
or in an Application Data Sheef under 37 CFR 1.76: Continuation Divisional Continuation Divisional Continuation Divisional Continuation-in-part (CIP) Divisional Divisional Continuation Divisional Continuation Divisional Continuation Divisional Di							
19. CORRESPONDENCE ADDRESS							
Customer Number or Bar Code Label (Insert Customer No: or Attach bar code label nere) Or X Correspondence address below							
Name Linda O. Palladino							
Regeneron Pharmaceuticals, Inc.							
Address	777 Old Saw Mill River Road						
City	Tarrytown State New York Zip Code 10591					10591	
Country	United States	Telephone	9 14- 345 - 7400	Fa	X	914-345-7721	
Name (Print/Type)	Linda O. Palladino	Regi	istration No. (Attorney	/Agent)	45	,636	
Signature	Auda O. Pallasino Date February 15, 20				ruary 15, 2002		

Burden Hour Statement: This form is estimated to take 0.2/hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

\$)	3.	762

Complete if Known			
Application Number	Nōt Yet Known		
Filing Date	Filed Herewith		
First Named Inventor	Andrew J. Murphy		
Examiner Name	Not Yet Known		
Group Art Unit	Not Yet Known		
Attorney Docket No.	REG 780D		

METHOD OF PAYMENT	FEE CALCULATION (continued)					
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES					
Deposit	Large Small Entity Entity					
Account 18-0650 Number	Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	Fee Paid				
Deposit Account Name Regeneron Pharmaceuticals, Inc.	105 130 205 65 Surcharge - late filing fee or oath					
Nettile Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet					
Applicant claims small entity status	139 130 139 130 Non-English specification					
See 37 CFR 1.27	147 2.520 147 2,520 For filing a request for ex parte reexamination					
Payment Enclosed: Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action					
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action					
	115 110 215 55 Extension for reply within first month					
BASIC FILING FEE Large Entity Small Entity	116 400 216 200 Extension for reply within second month					
Fee Fee Fee Fee Description	117 920 217 460 Extension for reply within third month					
Code (\$) Code (\$) Fee Paid	118 1,440 218 720 Extension for reply within fourth month					
101 740 201 370 Utility filing fee 740.	128 1,960 228 980 Extension for reply within fifth month					
106 330 206 165 Design filing fee	119 320 219 160 Notice of Appeal					
	120 320 220 160 Filing a brief in support of an appeal					
108 740 208 370 Reissue filing fee 114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing					
114 100 214 00 FTOVISIONAL MILITY TEE	138 1,510 138 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$) 740.	140 110 240 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES	141 1,280 241 640 Petition to revive - unintentional					
Fee from Extra Claims below Fee Paid	142 1,280 242 640 Utility issue fee (or reissue)					
Total Claims 107 -20** = 87 X 18. = 1,566.	143 460 243 230 Design issue fee					
Independent 17 - 3** = 14 X 84. = 1,176.	144 620 244 310 Plant issue fee					
Multiple Dependent 280. = 280.	122 130 122 130 Petitions to the Commissioner					
	123 50 123 50 Processing fee under 37 CFR 1 17(q)					
Large Entity Small Entity Fee Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt					
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)					
102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))					
104 280 204 140 Multiple dependent claim, if not paid	149 740 249 370 For each additional invention to be					
109 84 209 42 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))					
110 18 210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)					
and over original patent	169 900 169 900 Request for expedited examination of a design application					
SUBTOTAL (2) (\$) 3,022.	Other fee (specify)					
**or number previously paid, if greater; For Reissues, see above	**or number previously paid, if greater: For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3)					
Or number previously part, it greates, 1 or neasures, see above						

SUBMITTED BY					Complete (if applicable)			
Name (Print/Type)	Linda Q. Palladino	1	Registration No. (Attorney/Agent)	45,636	Telephone	914-345-7400		
Signature	Tudao.	Paela	deno		Date	February 15, 2002		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.